Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis: Induction of elevated serum adiponectin levels following therapy

British Journal of Dermatology

Volumn 164, Issue 3, 2011, Pages 667-670

  Shibata, S ^a   Tada, Y ^a   Hau, C ^a   Tatsuta, A ^a   Yamamoto, M ^a   Kamata, M ^a   Karakawa, M ^b   Asano, Y ^a   Mitsui, H ^a   Sugaya, M ^a   Kadono, T ^a   Saeki, H ^a   Kanda, N ^c   Sato, S ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ADIPONECTIN; COLECALCIFEROL; INFLIXIMAB; INTERLEUKIN 6; STEROID;

ADULT; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LETTER; MALE; PATHOGENESIS; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS SEVERITY INDEX; PSORIATIC ARTHRITIS; TREATMENT DURATION; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION;

ADIPONECTIN; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; ULTRAVIOLET THERAPY;

EID: 79952434300     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.10123.x     Document Type: Letter

References (10)

1. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784-92. (Pubitemid 44033298)
2. Sterry W, Strober BE, Menter A,. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007; 157: 649-55. (Pubitemid 47389868)
3. Shibata S, Saeki H, Tada Y, et al. Serum high molecular weight adiponectin levels are decreased in psoriasis patients. J Dermatol Sci 2009; 55: 62-3.
4. Takahashi H, Tsuji H, Takahashi I, et al. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol 2008; 159: 1207-8.
5. Peters MJ, Watt P, Cherry L, et al. Lack of effect of TNFalpha blockade therapy on circulating adiponectin levels in patients with autoimmune disease: results from two independent prospective studies. Ann Rheum Dis 2010; 69: 1687-90.
6. Fasshauer M, Kralisch S, Klier M, et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2003; 301: 1045-50. (Pubitemid 36279218)
7. Ouchi N, Walsh K,. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007; 380: 24-30. (Pubitemid 46498041)
8. Nickoloff BJ, Nestle FO,. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004; 113: 1664-75. (Pubitemid 39071656)
9. Chinetti G, Zawadski C, Fruchart JC, et al. Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR. Biochem Biophys Res Commun 2004; 314: 151-8. (Pubitemid 38058382)
10. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-6. (Pubitemid 32756432)